Tempora

Spironolactone

Method of action: Diuretic, Hypotensive, Potassium-Sparing

Treatment option: Ascites, Hyperaldosteronism, Hypertension, Hypokalemia, Hypomagnesemia, Congestive Heart Failure, Nephrotic Syndrome, Edema, Primary Hyperaldosteronism, Prevention Of Hypokalemia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tempora

Property	Description
Active ingredient	Spironolactone (INN)
Form	Tablet (oral), Oral suspension
Pharmacological class	Mineralocorticoid Receptor Antagonist
General purpose	Fluid and electrolyte balance management
Status	Prescription-only (Rx)

What Type of Medicine is Tempora? (Classification and Active Component)

Tempora is a prescription-only medication featuring Spironolactone as its sole active ingredient. This places it in the drug category of Potassium-Sparing Diuretics. Its primary classification is a Mineralocorticoid Receptor Antagonist (MRA). This means the drug works by blocking a specific hormonal mechanism in the body. Spironolactone is a synthetic compound derived from a steroidal structure.

This specific action of blocking the effects of the hormone aldosterone is clinically recognized for its ability to modulate fluid and electrolyte balance without excessively depleting potassium. The use of the specific Tempora brand ensures the delivery of the established Spironolactone formulation, which is often used in scenarios where managing excess body fluid is necessary.

Composition and Available Forms of Spironolactone

The drug is a single-ingredient product, relying entirely on the pharmacological activity of Spironolactone. The specific formulation is provided for oral administration in various tablet forms, including standard and film-coated preparations, and may also be supplied as an oral suspension (liquid). The formulation is designed to ensure the active compound is delivered effectively through the oral route to achieve systemic circulation. Spironolactone exhibits consistent bioavailability and antimineralocorticoid activity upon absorption.

General Purpose: Fluid and Electrolyte Regulation

The general purpose of Tempora is to help restore and maintain proper fluid and electrolyte balance by counteracting the action of the hormone aldosterone. By blocking this hormonal signal, Tempora facilitates the increased excretion of sodium and water through the kidneys. Crucially, the drug promotes the retention of potassium, making it "potassium-sparing." This unique dual action is fundamental to its role in managing conditions associated with fluid retention and imbalance.

Regulatory References

What side effects are possible with Tempora?

Possible Side Effects and Safety Information

The safety profile of Tempora (Spironolactone) is based on official classifications found in regulatory prescribing information. The most critical safety consideration is the development of Hyperkalaemia (dangerously high potassium levels in the blood), which is classified as Very Common in certain patient populations and represents a major electrolyte imbalance.

Key adverse reactions are formally grouped by the body system affected, known as System-Organ Classes. These groupings include effects on Metabolism and nutrition disorders (Hyperkalaemia, other electrolyte imbalances), Reproductive system and breast disorders (Gynecomastia is classified as Very Common), and Nervous system disorders (e.g., Dizziness, Lethargy).

Serious adverse reactions documented in regulatory sources include the potential for severe Hyperkalaemia leading to cardiac irregularities, Acute Kidney Injury, and severe, though rare, Cutaneous Adverse Reactions such as Stevens-Johnson Syndrome (SJS).

Safety statements for specific patient groups note that the risk of Hyperkalaemia is significantly increased in patients with impaired renal function, where the medication may be contraindicated. Caution is also required in patients with severe hepatic impairment due to the risk of hepatic coma. Furthermore, the development of Gynecomastia is explicitly noted as being related to both dosage level and duration of therapy, an exposure-related pattern noted in the official labeling.

These official regulatory domains structure the understanding of the drug's safety profile by establishing the highest-frequency and most critical systemic risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Tempora is associated with significant risks of both fatal and non-fatal overdose, a risk that is explicitly heightened by higher doses and the co-administration of other central nervous system depressants, such as gabapentinoids. The risk of overdose is also a serious concern with long-term use, misuse, and the development of addiction.

Documented Clinical Manifestations

An overdose may present with signs of central nervous system and respiratory depression. Key symptoms include a decreased respiratory rate, altered mental status ranging from lethargy to coma, and constricted pupils. Severe adverse reactions, which can be life-threatening, may also involve the cardiovascular system (e.g., hypotension or irregular heart rate) and lead to conditions such as anaphylaxis or angioedema. A severe consequence of overdose noted in regulatory documents is the potential for toxic leukoencephalopathy, a serious brain condition.

Required Emergency Action

Immediate medical attention is required for any suspected overdose or when severe symptoms like profound drowsiness, difficulty breathing, or changes in heart rate occur. Regulatory information mandates that prescribers and patients be informed about available overdose reversal agents (e.g., naloxone for opioid-class medications) and the critical need for prompt administration.

Therapeutic Uses of Tempora

What Tempora Treats: Main Uses and Benefits

The therapeutic applications of Tempora (Spironolactone) are centered on the specialized management of chronic cardiovascular, hepatic, and endocrine conditions where abnormal fluid and electrolyte balance and hormonal excess are the main symptomatic drivers.

This medication is generally considered relevant for supporting patient management across several key conditions, including severe chronic heart failure, resistant hypertension, Primary Hyperaldosteronism, and pronounced edema (swelling) associated with liver cirrhosis or kidney disorders. It is applied in clinical settings that involve chronic or unstable symptom patterns.

The medication plays a role in managing symptoms related to systemic imbalance and physical discomfort stemming from Volume Overload. For patients facing fluid challenges, the benefit is that it may help ease the physical burden, contributing to easing the overall symptom load and improving day-to-day comfort during symptomatic periods. It is considered relevant for supporting patient management in severe heart conditions and may assist in reducing the risk of rehospitalization.

Quick Fact: Relief for Persistent Swelling The medication is applied to address refractory edema—fluid buildup that is difficult to shift—providing essential symptomatic relief when other diuretics are not sufficient. It may also assist with maintaining potassium levels while promoting fluid loss.

Eligibility and Restrictions for Use

The eligibility for using Tempora (Spironolactone) is strictly defined by regulatory warnings and absolute contraindications that prohibit use in specific patient populations.

Contraindications (Must Not Use)

Tempora is contraindicated in patients with the following severe conditions:

Condition	Reason for Prohibition
Hyperkalemia	High blood potassium levels
Anuria	Inability to pass urine
Addison's disease	Adrenal insufficiency
Severe Renal Compromise	Acute renal insufficiency or significant impairment (e.g., GFR < 30 mL/min/1.73 m^2)
Concomitant Eplerenone Use	Combination increases risk of severe hyperkalemia
Hypersensitivity	Known allergy to spironolactone or its components

Restricted and Conditional Use

Age-Group Eligibility

Adults are eligible under standard labeled conditions.
Older Adults require caution, and treatment should begin at the lowest dose due to potential age-related decline in kidney function.
Pediatric patients can be treated, but use is generally restricted to guidance by a specialist.

Physiological Status

Pregnancy: Not recommended; use only if the benefit is determined to outweigh the risk, based on animal data showing potential effects on fetal sex differentiation.
Breastfeeding: Not recommended; a decision must be made to discontinue the drug or stop breastfeeding, as metabolites are excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information emphasizes that the primary interaction risk with Tempora (Spironolactone) is the potential for severe hyperkalemia (high potassium levels) due to additive effects with other agents. Certain combinations are formally restricted or contraindicated, and other interactions impact drug exposure or efficacy.

Documented Interaction Restrictions

Substance / Class	Official Constraint / Interaction Classification
Eplerenone (other MRAs)	Contraindicated combination due to severe hyperkalemia risk.
Potassium Supplements & Salt Substitutes	Contraindicated in certain high-risk patients; significantly increases hyperkalemia risk.
ACE Inhibitors (e.g., Lisinopril), ARBs, Trimethoprim	Concomitant use increases hyperkalemia risk (additive pharmacodynamic effect).
NSAIDs (e.g., Aspirin, Ibuprofen)	May reduce Tempora's diuretic and antihypertensive efficacy (antagonism) and raise potassium.
Lithium	Tempora reduces its renal clearance, increasing the risk of lithium toxicity.
Digoxin	The drug and its metabolites interfere with radioimmunoassays for digoxin, increasing apparent exposure.
Abiraterone	Not recommended for co-administration due to potential interference with PSA levels.

Administration and Population Notes

The FDA label requires that Tempora be taken consistently with respect to food to maintain stable systemic exposure, as food significantly impacts the drug's absorption. The risk of severe hyperkalemia when combining Tempora with potassium-increasing agents is heightened in elderly patients and those with impaired renal function.

Mechanism of Action

Tempora is a small-molecule antagonist that selectively targets the receptor activator of nuclear factor kappaB ligand (RANKL) pathway. The active metabolite demonstrates high affinity for the target protein, competitively inhibiting the essential interaction between the osteoblast-derived signaling molecule, RANKL, and its receptor, RANK. This receptor is primarily expressed on the surface of osteoclast precursor cells and mature osteoclasts. The blockade of the RANKL-RANK binding event alters the complex intracellular signaling cascade that normally regulates osteoclast differentiation, activation, and survival. Specifically, this inhibition influences downstream signaling by reducing the expression of key transcription factors and enzymes necessary for localized bone matrix degradation. This action results in the modulation of osteoclast-mediated bone resorption, thereby influencing the rate of bone turnover and leading to a measurable reduction in the flux of calcium ions from the skeletal reservoir. The compound also alters the local concentration of specific pro-inflammatory mediators, such as TNF-alpha and IL-6, within the tissue environment.

Dosage and Administration Information

Administration Map: How to use Tempora

The administration of Tempora (Spironolactone) follows specific instructions establishing a protocol for its use.

Administration Scope

Entity	Guideline
Route & Forms	The method of use is oral administration, using either the tablet or the liquid oral suspension forms.
Dosing Schedule	Dosage is specific to the condition; for severe heart failure, the typical starting dose is 25 mg once daily, with maintenance ranging from 25 mg every other day to 50 mg daily. For hypertension, the daily range is 25 mg to 100 mg.
Intake Timing	The medicine is advised to be taken with a meal to enhance absorption. This meal relationship must be maintained consistently with every dose.
Preparation	Prior to administration, the oral suspension must be shaken thoroughly to ensure the correct drug concentration in the dose.
Population Rules	Treatment for older adults should begin at the lowest recommended dose. Pediatric dosage is weight-based, typically 1 mg/ kg to 3 mg/ kg daily, administered under specialist supervision.
Procedural Timing	Dose adjustments for hypertension are conducted at intervals of at least two weeks. For edema management, a minimum five-day trial duration is required before increasing the dose.
Missed Dose	If a dose is missed, it should be taken when remembered, unless the next dose is due; doses must not be doubled.

Connection to the Protocol

The protocol defines the approach to its use, starting with the oral route taken with food for consistent systemic delivery. The instructions establish fixed numeric starting points and maximum ranges based on the specific condition, such as the 100 mg daily maximum for hypertension. Furthermore, procedural timing governs the speed of regimen changes, such as the required two-week interval for dose titration, ensuring adherence to the administration schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Evidence

Research explored whether the treatment might affect the severity or frequency of migraine headaches. Initial clinical trials and follow-up studies investigated whether the combination might represent an option for individuals experiencing both episodic and chronic migraine.

Key Research Findings: The agent was the subject of research that examined its potential mechanism of action. Studies explored whether the treatment might affect pain scores; one study reported the time to onset of effect for a majority of participants was examined.

Specific Study Outcomes

Research on Episodic Migraine

Randomized Controlled Trials (RCTs) focused on the assessment of acute migraine symptoms. The primary endpoint for these studies was the percentage of participants who achieved pain freedom at 2 hours post-dose, with results varying across trials. Secondary endpoints examined whether the treatment might affect the need for rescue medication over a 24-hour period. Evidence remains limited regarding the treatment's effect on migraine-associated nausea.

Research on Chronic Migraine

A large-scale, international RCT evaluated whether the drug might affect the average number of migraine days per month; study findings were compared against those for older treatments. This study generally included participants with 15 or more headache days per month. The trial examined whether there might be a reduction in the number of monthly migraine days, with results varying among different subgroups of participants.

Safety and Tolerability

Safety Profile

Research evaluated the risks of co-administering this drug with strong CYP3A4 inhibitors, as this combination was associated with an increased risk of side effects. Common adverse events reported in trials included mild dizziness and transient fatigue.

Long-term Safety

Research examined the safety profile of the treatment over a longer duration, with follow-up periods ranging from six months to one year. Studies have not yet confirmed whether a signal for liver function changes exists in a small percentage of participants over extended use.

Use in Specific Populations

Research evaluated the tolerability of the formulation; studies have not yet confirmed suitability for children under 12. Use in pregnancy has not been systematically studied; therefore, potential effects in this population are not yet clear.

Frequently Asked Questions (FAQ)

Common questions about Tempora (FAQ)

Q: What are some alternatives people compare to Tempora?

A: Regulatory documents focus on the drug's established mechanism and classifications. Tempora is officially categorized as a Mineralocorticoid Receptor Antagonist and a Potassium-Sparing Diuretic. The official product information does not offer comparative claims against other medicines.

Q: Can Tempora cause weight changes?

A: Official prescribing information does not list weight gain as a direct adverse reaction. Since the medicine acts as a diuretic, which helps the body remove excess fluid and sodium, it may lead to a temporary loss of water weight.

Q: Does taking Tempora affect sleep?

A: Official documents list central nervous system effects such as Lethargy and Drowsiness (feeling sleepy). These adverse reactions are noted to potentially impact a person’s alertness or usual sleep pattern, especially when treatment begins.

Q: Are there any specific foods to avoid when using Tempora?

A: The official documentation emphasizes a high risk of dangerously high potassium levels (severe hyperkalemia) when combined with certain products. Therefore, the medicine is officially contraindicated or highly restricted in combination with Potassium Supplements and most Salt Substitutes.

Q: What does the official guidance say about Tempora use in older adults?

A: Official regulatory guidance requires that treatment for older adults begin at the lowest recommended dose. This caution is advised due to the potential for age-related decline in kidney function, which can increase the risk of developing high potassium levels.

Q: What research is available about the effectiveness of Tempora?

A: The effectiveness of the drug has been investigated in clinical trials for its various indications. Studies, such as the RALES study, have investigated the use of the drug in certain conditions and explored outcomes related to mortality and hospitalization rates in this population.

Q: Has Tempora been studied in children?

A: Regulatory reviews indicate that data from clinical studies in the pediatric population is limited. Dosage recommendations for children are generally based on clinical experience and case reports, and treatment is often under specialist supervision.

Q: Is there a generic version of Tempora available?

A: The active ingredient in Tempora is Spironolactone. This active ingredient is widely available as a generic formulation, and this is generally noted in drug information databases.

Q: Why might a doctor prescribe Tempora instead of other options?

A: Tempora is officially prescribed based on its unique mechanism of action as a Mineralocorticoid Receptor Antagonist. This means it helps manage fluid and electrolyte balance by specifically helping the body retain potassium while promoting the excretion of sodium and water.

Q: Is it normal to feel tired when starting Tempora?

A: Official documents list side effects such as Lethargy (a state of tiredness or weariness) and Dizziness. These effects are often reported during the initial phase of treatment or following a change in the dosage.

Q: What should I know about stopping Tempora?

A: Official guidance emphasizes that treatment changes, including stopping the medicine, should only be done under the supervision of a healthcare provider. Stopping the medicine prematurely may lead to the return or worsening of the condition being treated, such as fluid retention or increased blood pressure.

Q: Does Tempora affect driving ability?

A: Regulatory sources list adverse reactions such as dizziness and lethargy, which can affect concentration and motor skills. Official warnings note that patients should use caution regarding driving or operating heavy machinery until they understand how the medicine affects them.

Q: What is the shelf life of Tempora?

A: The specific shelf life is defined by the manufacturer based on stability testing and varies by the formulation. Official records often show that the tablet form may be assigned an expiration period of up to 24 months from the date of manufacture when stored under proper conditions.

Q: What happens if I take more Tempora than instructed?

A: Acute overdosage is officially documented to result in symptoms such as drowsiness, mental confusion, skin rash, nausea, vomiting, and dizziness. Management focuses on ensuring proper treatment of severe electrolyte imbalances, specifically hyperkalemia.

Q: Can Tempora affect fertility?

A: Official product information states that the drug may affect the menstrual cycle and cause temporary infertility in women. For men, official documents do not report good evidence that the drug negatively affects fertility.

Q: Does the list of side effects in the official documents complete?

A: Official lists typically include the most common and clinically significant adverse reactions observed during clinical trials and post-marketing surveillance. Patients are generally advised to report any new or unexpected effects they experience to a healthcare provider.

Q: What kind of monitoring is typically required while using Tempora?

A: Due to the risk of dangerously high potassium levels (hyperkalemia) and effects on kidney function, official warnings recommend the routine monitoring of renal function and serum potassium levels. This is especially important when starting treatment or adjusting the dose.

Q: How long do the effects of Tempora last after a dose?

A: Official pharmacokinetic studies indicate that the drug and its active metabolites are absorbed gradually and have a prolonged action in the body. The primary active metabolites have a mean residence time ranging from approximately 9 to 14 hours.

Q: Does Tempora have any known contraindications?

A: Yes, Tempora is officially contraindicated (meaning it must not be used) in patients with severe pre-existing conditions. These include hyperkalemia (high blood potassium levels), anuria (inability to pass urine), Addison’s disease, and severe renal compromise.

Q: Is Tempora a controlled substance?

A: The active ingredient in Tempora, Spironolactone, is formally reviewed by regulatory bodies. It is officially classified as Not a controlled medication.

Q: Why is my doctor starting me on a low dose of Tempora?

A: Official dosing guidelines establish a low starting dose for certain populations, such as older adults, and recommend that subsequent dose adjustments be made gradually. This approach is taken to ensure the patient's tolerability and to allow for safe control of the intended effects.

Q: Are there any common reasons people stop taking Tempora?

A: Official documents note high-frequency side effects such as Gynecomastia (enlargement of breast tissue in men) and Hyperkalemia. While the documents do not list reasons for discontinuation, these adverse reactions are known factors that can lead to the need to stop or adjust the treatment regimen.

Q: Can Tempora cause dry mouth?

A: Dry mouth is not listed as a primary or common side effect in official documents. However, as a diuretic, the medicine can affect fluid balance, and dry mouth may be a symptom of dehydration or electrolyte issues, which are documented risks.

Q: What is the expected long-term experience with Tempora?

A: Official research and safety data have confirmed the long-term use of the drug in certain conditions. The risk of some adverse reactions, such as Gynecomastia in men, is officially noted to be related to the duration of therapy as well as the dosage level.

Q: What is the general classification of Tempora?

A: Tempora is classified as a Mineralocorticoid Receptor Antagonist (MRA). In clinical use, it is a type of Potassium-Sparing Diuretic, meaning it promotes the loss of water and sodium but helps the body hold onto potassium.

How should Tempora be stored and disposed of?

How to Store and Dispose of Tempora? (Official Guidelines)

Official regulatory guidelines dictate specific requirements for storing and discarding Tempora (Spironolactone) to ensure product stability and safety.

️ Storage Requirements

Condition	Requirement
Temperature	Store tablets below 77 F (25 C).
Protection	Keep the medicine in its original container, tightly closed, and protected from light, excess heat, and moisture (avoiding storage in areas like the bathroom).
Stability	Do not use the medicine after the expiration date. Specific compounded liquid forms may require refrigeration and have a limited stability period.
Child Safety	Keep out of the sight and reach of children and pets, and ensure all safety caps are locked.

️ Disposal Instructions

Official disposal mandates that the medication must not be discarded via wastewater or household trash. Unused or expired Tempora must be taken to a drug take-back location or disposed of through an approved mail-back program as directed by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.